Can Indian Avastin Events Add To Roche's Take On Off-Label Use?
This article was originally published in Scrip
Executive Summary
Can the unfortunate events in India concerning Roche's Avastin (bevacizumab) add weight to the Swiss multinational's arguments that the off-label use of the anticancer may pose health risks, especially in the backdrop of the controversial reimbursement decision in markets like France?